already FDA approved drugs found to cross blood-brain barrier, prevent bc brain mets

[Lani]

two are listed in the abstract... full article discusses more and looks at both her2+ and her2- bc brain met prevention

this is still in rodents...Clinical trials need to speed this up!

Cancer Res. 2013 Oct 4. [Epub ahead of print]
Novel Modeling of Cancer Cell Signaling Pathways Enables Systematic Drug Repositioning for Distinct Breast Cancer Metastases.
Zhao H, Jin G, Cui K, Ren D, Liu T, Chen P, Wong S, Li F, Fan Y, Rodriguez A, Chang J, Wong ST.
Source
Authors' Affiliations: Department of Systems Medicine and Bioengineering; NCI Center for Modeling Cancer Development, The Methodist Hospital Research Institute, Weill Cornell Medical College; Methodist Cancer Center, The Methodist Hospital; Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston; and The University of Texas at Austin, Austin, Texas.
Abstract
A new type of signaling network element, called cancer signaling bridges (CSB), has been shown to have the potential for systematic and fast-tracked drug repositioning. On the basis of CSBs, we developed a computational model to derive specific downstream signaling pathways that reveal previously unknown target-disease connections and new mechanisms for specific cancer subtypes. The model enables us to reposition drugs based on available patient gene expression data. We applied this model to repurpose known or shelved drugs for brain, lung, and bone metastases of breast cancer with the hypothesis that cancer subtypes have their own specific signaling mechanisms. To test the hypothesis, we addressed specific CSBs for each metastasis that satisfy (i) CSB proteins are activated by the maximal number of enriched signaling pathways specific to a given metastasis, and (ii) CSB proteins are involved in the most differential expressed coding genes specific to each breast cancer metastasis. The identified signaling networks for the three types of breast cancer metastases contain 31, 15, and 18 proteins and are used to reposition 15, 9, and 2 drug candidates for the brain, lung, and bone metastases. We conducted both in vitro and in vivo preclinical experiments as well as analysis on patient tumor specimens to evaluate the targets and repositioned drugs. Of special note, we found that the Food and Drug Administration-approved drugs, sunitinib and dasatinib, prohibit brain metastases derived from breast cancer, addressing one particularly challenging aspect of this disease. Cancer Res; 73(20); 1-15. ©2013 AACR.
PMID: 24097821